1. The aim of the present study was to test the hypothesis that increasing kidney tissue concentrations of epoxyeicosatrienoic acids (EETs) by preventing their degradation to the biologically inactive dihydroxyeicosatrienoic acids (DHETEs) using blockade of soluble epoxide hydrolase (sEH) would attenuate the progression of chronic kidney disease (CKD). 2. Ren-2 transgenic rats (TGR) after 5/6 renal mass reduction (5/6 NX) served as a model of CKD associated with angiotensin (Ang) II-dependent hypertension. Soluble epoxide hydrolase was inhibited using cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid (c-AUCB; 3 mg/L drinking water) for 20 weeks after 5/6 NX. Sham-operated normotensive transgene-negative Hannover Sprague-Dawley (HanSD) rats served as controls. 3. When applied in TGR subjected to 5/6 NX, c-AUCB treatment improved survival rate, prevented the increase in blood pressure, retarded the progression of cardiac hypertrophy, reduced proteinuria and the degree of glomerular and tubulointerstitial injury and reduced glomerular volume. All these organ-protective actions were associated with normalization of the intrarenal EETs:DHETEs ratio, an index of the availability of biologically active EETs, to levels observed in sham-operated HanSD rats. There were no significant concurrent changes of increased intrarenal AngII content. 4. Together, these results show that 5/6 NX TGR exhibit a profound deficiency of intrarenal availability of active epoxygenase metabolites (EETs), which probably contributes to the progression of CKD in this model of AngII-dependent hypertension, and that restoration of intrarenal availability of EETs using long-term c-AUCB treatment exhibits substantial renoprotective actions.

Center for Experimental Medicine Institute for Clinical and Experimental Medicine Charles University Prague Czech Republic; Department of Pathology 3rd Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

US Renal Data System. USEDS 2012 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012.

Brenner BM. Nephron adaptation to renal injury or ablation. Am. J. Physiol. 1985;249:F324–37. PubMed

Zoja C, Abbate M, Remuzzi G. Progression of chronic kidney disease: Insight from animal models. Curr. Opin. Nephrol. Hypertens. 2006;15:250–7. PubMed

Hostetter TH. Hyperfiltration and glomerulosclerosis. Semin. Nephrol. 2003;23:194–9. PubMed

Hostetter TH, Olson JL, Rennke HG, Ventatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: A potentially adverse response to ablation. Am. J. Physiol. 1981;241:F85–93. PubMed

Shimamura T, Morrison AB. A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am. J. Pathol. 1975;79:95–106. PubMed PMC

Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Micros. Res. Tech. 2002;57:189–95. PubMed

Macconi D. Targeting the renin angiotensin system for remission/regression of chronic kidney disease. Histol. Histopathol. 2010;25:655–68. PubMed

Kohan DE. Endothelin, hypertension and chronic kidney disease: New insight. Curr. Opin. Nephrol. Hypertens. 2010;19:134–9. PubMed PMC

Briet M, Burns KD. Chronic kidney disease and vascular remodeling. Molecular mechanisms and clinical implications. Clin. Sci. 2012;123:399–416. PubMed

Vanecková I, Kujal P, Husková Z, et al. Effects of combined endothelin a receptor and renin–angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats. Kidney Blood Press. Res. 2012;35:382–92. PubMed

Kujal P, Certíková Chábová V, Vernerova Z, et al. Similar renoprotection after renin–angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: Are there blood pressure-independent effects? Clin. Exp. Pharmacol. Physiol. 2010;37:1159–69. PubMed

Bidani AK, Polichnowski AJ, Loutzenhiser R, Griffin KA. Renal microvascular dysfunction, hypertension and CKD progression. Curr. Opin. Nephrol. Hypertens. 2013;22:1–9. PubMed PMC

Ptinopolou AG, Pikilidou MI, Lasaridis N. The effect of antihypertensive drugs on chronic kidney disease: A comprehensive review. Hypertens. Res. 2013;36:91–101. PubMed

Turner JM, Bauer C, Abramowitz MK, Melamed ML, Hostetter TH. Treatment of chronic kidney disease. Kidney Int. 2012;81:351–62. PubMed

Rüster C, Wolf G. Renin–angiotensin–aldosterone system and progression of renal disease. J. Am. Soc. Nephrol. 2006;17:2985–91. PubMed

Berl T. Renal protection by inhibition of the renin–angiotensin–aldosterone system. J. Renin Angiotensin Aldosterone Syst. 2009;10:1–8. PubMed

Perico N, Amuchastegui SC, Colosio V, Sonzogni G, Bertani T, Remuzzi G. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J. Am. Soc. Nephrol. 1994;5:1139–46. PubMed

Gordon J, Kopp JB. Off the beaten renin–angiotensin–aldosterone system pathway: New perspectives on antiproteinuric therapy. Adv. Chronic Kidney Dis. 2011;18:300–11. PubMed PMC

Lattanzio MR, Weir MR. Does blockade of the renin–angiotensin–aldosterone system slow progression of all forms of kidney disease? Curr. Hypertens. Rep. 2010;12:369–77. PubMed

Campbell WB, Fleming I. Epoxyeicosatrienoic acids and endothelium-dependent response. Pfugers Arch. 2010;459:881–95. PubMed PMC

Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol. Rev. 2012;92:101–30. PubMed PMC

Capdevilla J, Wang W. Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension. Curr. Opin. Nephrol. Hypertens. 2013;22:163–9. PubMed PMC

Elmarakby AA. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012;302:R321–30. PubMed

Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front. Biosci. 2008;13:3480–7. PubMed

Huang H, Morisseau C, Wang JF, et al. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am. J. Physiol. Renal Physiol. 2007;293:F342–9. PubMed

Sporková A, Kopkan L, Varcabová A, et al. Role of cytochrome P450 metabolites in the regulation of renal function and blood pressure in 2-kidney, 1-clip hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011;300:R1468–75. PubMed PMC

Neckár J, Kopkan L, Husková Z, et al. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-I-ylureido) cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin. Sci. 2012;122:513–25. PubMed PMC

Honetschlägerová Z, Husková Z, Vanourkova Z, et al. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J. Physiol. 2011;589:207–19. PubMed PMC

Kopkan L, Husková Z, Sporková A, et al. Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. Kidney Blood Press. Res. 2012;35:595–607. PubMed PMC

Honetschlägerová Z, Sporková A, Kopkan L, et al. Inhibition of soluble epoxide hydrolase improves the impaired pressure–natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J. Hypertens. 2011;29:1590–601. PubMed PMC

Honetschlägerová Z, Kitada K, Husková Z, et al. Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with l-NAME. J. Hypertens. 2013;31:321–32. PubMed PMC

Zhao G, Tu L, Li X, et al. Delivery of AAV2-CYP2J2 protects remnant kidney in the 5/6-nephrectomized rat via inhibition of apoptosis and fibrosis. Hum. Gene Ther. 2012;23:688–99. PubMed

Jung O, Jansen F, Mieth A, et al. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One. 2010;5:e11979. PubMed PMC

Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature. 1990;344:541–4. PubMed

Ripley E. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease. Am. Heart J. 2009;157(Suppl):S7–16. PubMed

Čertíková Chábová V, Walkowska A, Kompanowska-Jezierska E, et al. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin. Sci. 2010;118:617–32. PubMed PMC

Williams JM, Murphy S, Burke M, Roman RJ. 20-Hydroxyeicosatetraenoic acid. A new target for the treatment of hypertension. J. Cardiovasc. Pharmacol. 2010;56:336–44. PubMed PMC

Ai D, Fu Y, Guo D, et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc. Natl Acad. Sci. USA. 2007;104:9018–23. PubMed PMC

Ai D, Shyy JYY, Zhu Y. Linking an insect enzyme to hypertension: Angiotensin II–epoxide hydrolase interactions. Kidney Int. 2010;77:88–92. PubMed

Yoshida Y, Fogo A, Shiraga H, Glick AD, Ichikawa I. Serial micropuncture analysis of single nephron function in subtotal renal ablation. Kidney Int. 1988;33:855–67. PubMed

Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J. Clin. Invest. 1988;82:322–30. PubMed PMC

Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int. 1989;35:654–60. PubMed

Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I. Effects of antihypertensive drugs on glomerular morphology. Kidney Int. 1989;36:626–35. PubMed

Fukuda A, Wickman LT, Vekatareddy MP, et al. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end-stage kidney disease. Kidney Int. 2012;81:40–55. PubMed PMC

Guarino M, Tosoni A, Nebuloni M. Direct contribution of epithelium to organ fibrosis: Epithelial–mesenchymal transition. Hum. Pathol. 2009;40:1365–76. PubMed

Ni H, Chen J, Pan M, et al. FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease. J. Mol. Histol. 2013;44:693–703. PubMed

Barnes JL, Gorin Y. Myofibroblast differention during fibrosis. Role of NAD(P)H oxidases. Kidney Int. 2011;79:944–56. PubMed PMC

Kopkan L, Husková Z, Vanourková Z, et al. Reduction of oxidative stress does not attenuate the development of angiotensin II-dependent hypertension in Ren-2 transgenic rats. Vasc. Pharmacol. 2009;51:175–81. PubMed

Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin–angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 2007;59:251–87. PubMed

Husková Z, Vanourková Z, Erbanová M, et al. Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbate hypertension in Cyp1a1-Ren-2 transgenic rats. J. Hypertens. 2010;28:495–509. PubMed

Vanourková Z, Kramer HJ, Husková Z, et al. AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J. Hypertens. 2006;24:2465–72. PubMed

Červenka L, Vanečková I, Husková Z, et al. Pivotal role of AT1A receptors in the development of two-kidney, one-clip hypertension: Study in AT1A receptor knockout mice. J. Hypertens. 2008;26:1379–89. PubMed PMC

Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME. Additive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin. Sci. 2001;100:591–9. PubMed

Fujihara CK, Velho M, Malheiros DM, Zatz R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int. 2005;67:1913–24. PubMed

Huskova Z, Kramer HJ, Thumova M, et al. Effects of anesthesia on plasma and kidney ANG II levels in normotensive and ANG II-dependent hypertensive rats. Kidney Blood Press. Res. 2006;29:74–83. PubMed

Husková Z, Kramer HJ, Vanourková Z, Červenka L. Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J. Hypertens. 2006;24:517–27. PubMed

Varcabova S, Huskova Z, Kramer HJ, et al. Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin–angiotensin system. Clin. Exp. Pharmacol. Physiol. 2013;40:273–81. PubMed PMC

Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE. Recommendations for blood pressure measurements in humans and experimental animals. Part 2: Blood pressure measurements in experimental animals. Hypertension. 2005;45:299–310. PubMed

Nakano Y, Hirano T, Uehara K, et al. New rat model induced by anti-glomerular basement membrane antibody shows severe glomerular adhesion in early stage and quickly progress to end-stage renal failure. Pathol. Int. 2008;58:361–70. PubMed

Lane PH, Steffes MW, Mauer MS. Estimation of glomerular volume: A comparison of four methods. Kidney Int. 1992;41:1085–9. PubMed

Transgenic rat with ubiquitous expression of angiotensin-(1-7)-producing fusion protein: a new tool to study the role of protective arm of the renin-angiotensin system in the pathophysiology of cardio-renal diseases

The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula

Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats

Contribution of selected vasoactive systems to blood pressure regulation in two models of chronic kidney disease

Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats

Epoxyeicosanoids in hypertension

Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats

Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats

Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease

Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula

Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats